Denver, CO – March 23, 2021 — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that effective as of market open today, March 23, 2021, its common shares and warrants have been approved for migration to the NEO Exchange and will commence trading under ticker symbols “MYCO” and “MYCO.WT,” respectively.
“Mydecine is quickly solidifying its position within the emerging psychedelic-assisted therapeutic industry as we build a robust R&D pipeline focused on the usage of psychedelic medicines to treat mental health disorders and deliver on multiple industry firsts. While we diligently work on our drug development, we also remain committed to providing greater visibility within the investment community. The NEO Exchange enables us to reach a broader institutional and retail investor audience and in turn enhance shareholder value,” said Josh Bartch, CEO and Co-Founder of Mydecine.
“This listing occurs on the cusp of completing a key operational milestone of achieving the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to our cGMP facility in Canada. With a commercial supply chain of psilocybin mushrooms now in place, we are strongly positioned to advance several initiatives aimed at driving the future of alternative nature-sourced medicine for mainstream use. We look forward to the support of the NEO Exchange and increased capital markets exposure as Mydecine builds our leadership position within this rapidly developing industry,” concluded Mr. Bartch.
